The Task Force for Global Health Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
The mission of The Task Force for Global Health is to solve large-scale health problems affecting populations through three impact areas: health system strengthening, center for vaccine equity, and neglected tropical diseases. These impact areas include programs such as pandemic preparedness, polio eradication, field epidemiology training, public health informatics, health workforce development, and medical surplus recovery.
- Income
- $114.0 million
- Spending
- $89.6 million
- Spent on programs
- 84%
- Reserves
- 1.5 months of spending
- Largest source of income
- donations and private grants, 70%
- Employees
- 233
- Volunteers
- 4
- Highest pay
- $397,023, president & ceo
Source: Form 990 for the year ending August 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 71 out of 100. Higher than 69% of charities in its peer group (human services, over $100m).
Reserves
10 of 35Spendable reserves would cover 1.5 months of spending.
Debt
16 of 20It owes 21% of what it owns.
Living within its means
15 of 15Income exceeded spending by 21% of income.
Income trend
15 of 15Income rose 18% on the year before.
Spending floor
15 of 1584% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending August 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 29% of charities in its peer group (human services, over $100m).
Independent board
25 of 2510 of 11 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending August 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (8)
- $17.7 million spent. Respiratory Virus Prevention and Preparedness Programs Partnership for International Vaccine Initiatives (PIVI) Program Description: PIVI works to reduce global disease burden from influenza and improve capacity to respond to pandemic threats. Program Objectives: * FY2024: Increase programmatic experience and local evidence to drive government investment in national influenza vaccination programs. * Long-term: Establish sustainable national influenza vaccination programs to reduce global influenza burden and pandemic threat. Accomplishments: * Expanded to 28 partner countries (net growth of 7 countries during FY2024) * Donated 105,000 influenza vaccine doses (valued at $454,000) to 5 partner countries * Provided $1,120,000 in subawards to 17 partner countries * Supported 11 countries in transitioning from PIVI vaccine support to self-funded programs * Facilitated purchase of approximately 2,100,000 vaccine doses by transitioning countries * Documented improved vaccine access and coverage in 95% of partner countries with more than 1 year of support * Trained an estimated 500+ healthcare professionals in vaccine delivery and program management
- $11.2 million spent. Funded principally by the Bill & Melinda Gates Foundation and the U.S. Agency for International Development, the NTD-SC supports Operational Research (OR) to eliminate neglected tropical diseases that threaten the lives and well-being of more than one billion people in some of the world's poorest communities, serving as the Secretariat for the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD). As of 2024, the NTD-SC managed a portfolio of more than 330 OR projects spanning 60 countries, and targeting all five neglected tropical diseases amenable to preventive chemotherapy: lymphatic filariasis, onchocerciasis, STH, schistosomiasis and trachoma, as well as other NTDs such as podoconiosis, leprosy and leishmaniasis. OR projects are designed to address challenges that prevent programs from achieving disease control and elimination goals and to inform World Health Organization (WHO) recommendations and guidance for NTD programs. In 2024, COR-NTD convened NTD Operational Research meetings in New Delhi, India and Brisbane, Australia in collaboration with regional WHO offices, ministries of health and local research partners, and completed the planning for a pioneering Africa-based operational research meeting on NTDs, in partnership with the African Research Network on NTDs, to take place in Kigali, Rwanda in early 2025. These regional conferences bring together researchers and country program managers and implementers to address the challenges faced by NTD programs that prevent the shared goal of eliminating these infections. With support from USAID in 2024, the NTD-SC also issued calls for proposals to support research focused on migrant and mobile populations and continued to support the African Research Network for Neglected Tropical Diseases (ARNTD) Small Grants Program. ARNTD manages a portfolio of research projects carried out by young African scientists at early stages of their careers and in 2024 the ARNTD call for proposals was also expanded to mid-career researchers for the first time. During the period, the NTD-SC also conducted a competitive process to identify Africa-based partners to transition the procurement of research supplies from a US-based to Africa-based supply chain.
- $10.8 million spent. The International Trachoma Initiative (ITI) works tirelessly for a world free from trachoma. ITI contributes to eliminating trachoma as a public health threat by stewarding Pfizer's donation of azithromycin to treat and prevent the condition; building and strengthening partnerships to accelerate progress; and developing innovative tools to share data. Between September 2024 and August 2025, ITI organized just-in-time shipments of 44.6 million treatments for trachoma to be distributed at MDAs in 12 countries. As of August 2025, ITI has shipped more than 1.117 billion treatments to trachoma-endemic countries since the program's inception in 1999. ITI continued its data management support for Tropical Data, a free mobile phone-based service to support trachoma programs as they conduct prevalence surveys, providing them with robust data for decision-making on where antibiotic treatments are needed and where they can be stopped. Since its inception in February 2016, Tropical Data has supported over 4,136 surveys across 55 countries. As a key player in the global trachoma community, there have been tremendous achievements in reducing the population at risk of blindness from trachoma from an estimated 1.5 billion people in 2002 to 97.1 million in November 2025 according to the World Health Organization (WHO). ITI will continue to work smarter so that the dream of a trachoma-free world becomes a reality. In addition to ITI's work in trachoma, ITI was awarded a grant from the Gates Foundation in August 2024 to expand into the donation of azithromycin for child survival. Between September 2024 and August 2025, ITI organized just-in-time shipments of 22.8 million treatments for child survival to be distributed at MDAs in 3 countries.
- $6.7 million spent. Public Health Informatics Institute
- $6.4 million spent. Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET)
- $6.1 million spent. Polio Eradication
- $6.1 million spent. Vacine Safety
- $9.8 million spent. Other Programs
Source: Form 990 for the year ending August 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending August 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since November 1986.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.